BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huo TI, Wu JC, Hsia CY, Chau GY, Lui WY, Huang YH, Lee PC, Chang FY, Lee SD. Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas. World J Surg 2004;28:787-91. [PMID: 15457359 DOI: 10.1007/s00268-004-7320-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Thuluvath PJ, Maheshwari A, Thuluvath NP, Nguyen GC, Segev DL. Survival after liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease and pre-model for end-stage liver disease eras and the independent impact of hepatitis C virus: Post-LT Survival for HCC and Impact of HCV. Liver Transpl 2009;15:754-62. [DOI: 10.1002/lt.21744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
2 Wang C, Iyer SG, Low JK, Lin C, Wang S, Lu S, Chen C. Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Ann Surg Oncol 2009;16:1832-42. [DOI: 10.1245/s10434-009-0448-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
3 Huo T, Wu J, Lin H, Lee F, Hou M, Huang Y, Lee P, Chang F, Lee S. Determination of the optimal model for end-stage liver disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl 2004;10:1507-13. [DOI: 10.1002/lt.20310] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
4 Squires MH, Hanish SI, Fisher SB, Garrett C, Kooby DA, Sarmiento JM, Cardona K, Adams AB, Russell MC, Magliocca JF. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol. 2014;109:533-541. [PMID: 24347475 DOI: 10.1002/jso.23531] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
5 Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol. 2007;14:1835-1845. [PMID: 17406950 DOI: 10.1245/s10434-007-9366-z] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 6.0] [Reference Citation Analysis]
6 Wei Y, Yi Y, Tao C, Ye W, Zhao W. Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas. Cancer Manag Res 2019;11:8475-86. [PMID: 31572002 DOI: 10.2147/CMAR.S201744] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Zhou Y, Si X, Wu L, Su X, Li B, Zhang Z. Influence of viral hepatitis status on prognosis in patients undergoing hepatic resection for hepatocellular carcinoma: a meta-analysis of observational studies. World J Surg Oncol. 2011;9:108. [PMID: 21933440 DOI: 10.1186/1477-7819-9-108] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
8 Shah SA, Cleary SP, Tan JC, Wei AC, Gallinger S, Grant DR, Greig PD. An analysis of resection vs transplantation for early hepatocellular carcinoma: defining the optimal therapy at a single institution. Ann Surg Oncol. 2007;14:2608-2614. [PMID: 17522942 DOI: 10.1245/s10434-007-9443-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.9] [Reference Citation Analysis]
9 Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y. Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC. Intervirology. 2007;50:24-31. [PMID: 17164554 DOI: 10.1159/000096309] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
10 Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007;31:1243-8. [PMID: 17440771 DOI: 10.1007/s00268-007-9041-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 4.6] [Reference Citation Analysis]
11 Chirica M, Tranchart H, Tan V, Faron M, Balladur P, Paye F. Infection with hepatitis C virus is an adverse prognostic factor after liver resection for early-stage hepatocellular carcinoma: implications for the management of hepatocellular carcinoma eligible for liver transplantation. Ann Surg Oncol. 2013;20:2405-2412. [PMID: 23338483 DOI: 10.1245/s10434-012-2861-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
12 Shimada K, Sakamoto Y, Esaki M, Kosuge T. Role of the width of the surgical margin in a hepatectomy for small hepatocellular carcinomas eligible for percutaneous local ablative therapy. The American Journal of Surgery 2008;195:775-81. [DOI: 10.1016/j.amjsurg.2007.06.033] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
13 Chen BB, Shih IL, Wu CH, Hsu C, Chen CH, Shih TT, Liu KL, Liang PC. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies. J Vasc Interv Radiol. 2014;25:371-378. [PMID: 24468045 DOI: 10.1016/j.jvir.2013.10.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
14 Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res 2012;24:36-43. [PMID: 23359473 DOI: 10.1007/s11670-012-0036-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
15 Ohki T, Tateishi R, Akahane M, Shiina S, Yamashiki N, Mikami S, Enooku K, Goto E, Masuzaki R, Kondo Y, Goto T, Inoo S, Ohtomo K, Omata M, Yoshida H, Koike K. Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial. Hepatol Int 2012;6:639-45. [PMID: 22020826 DOI: 10.1007/s12072-011-9310-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
16 Huo TI, Huang YH, Hsia CY, Su CW, Lin HC, Hsu CY, Lee PC, Lui WY, Loong CC, Chiang JH, Chiou YY, Lee SD. Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: are they different from patients with single virus infection? Liver Int 2009;29:767-73. [PMID: 19018974 DOI: 10.1111/j.1478-3231.2008.01908.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
17 Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573-4591. [PMID: 32167932 DOI: 10.18632/aging.102913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]